Key Points
- AtriCure insider Salvatore Privitera sold 4,519 shares at an average price of $60, generating proceeds of $271,140. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 142,745 shares.
- AtriCure reported quarterly EPS of $0.18 on revenue of $153.6 million, exceeding the $151.8 million revenue estimate. The company issued fiscal 2026 EPS guidance of $0.24 to $0.32.
- Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $53.30, while the stock recently traded near its 12-month high at $60.77.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Salvatore Privitera sold 4,519 shares of the business's stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the sale, the insider owned 142,745 shares of the company's stock, valued at $8,564,700. This represents a 3.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Salvatore Privitera also recently made the following trade(s):
- On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
- On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.
AtriCure Price Performance
Shares of NASDAQ:ATRC opened at $60.77 on Friday. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $61.70. The firm has a market capitalization of $3.09 billion, a P/E ratio of 289.39 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The company's fifty day moving average price is $46.76 and its 200 day moving average price is $35.29.
AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on ATRC. BTIG Research upped their target price on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, August 24th. Stifel Nicolaus set a $65.00 price target on AtriCure in a research report on Thursday, September 17th. Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Citigroup reissued a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $53.30.
Get Our Latest Report on ATRC
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Harbor Investment Advisory LLC purchased a new stake in AtriCure in the 2nd quarter valued at approximately $40,000. Allworth Financial LP acquired a new position in AtriCure during the 2nd quarter worth approximately $43,000. Integrated Wealth Concepts LLC purchased a new position in shares of AtriCure during the 2nd quarter worth approximately $46,000. Fifth Third Bancorp purchased a new position in shares of AtriCure during the 1st quarter worth approximately $51,000. Finally, Global Retirement Partners LLC purchased a new position in shares of AtriCure during the 2nd quarter worth approximately $52,000. 99.11% of the stock is owned by hedge funds and other institutional investors.
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.
Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
